Journal article
Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma
Bone marrow transplantation (Basingstoke), Vol.19(8), pp.777-781
1997
DOI: 10.1038/sj.bmt.1700733
PMID: 9134168
Abstract
The combination of busulfan and cyclophosphamide has seldom been employed as a conditioning regimen for patients with lymphoma. Twenty patients with relapsed or refractory lymphoma were treated with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) (BU/CY) followed by peripheral blood stem cell rescue in 19 patients or autologous bone marrow in one patient. There were 12 females and eight males, with a median age of 48 years (range 30–65). Four patients had Hodgkin’s disease, and 16 patients had non-Hodgkin’s lymphoma. Disease status at the time of BU/CY was: first relapse in 10 patients (four patients with chemosensitive disease and six patients with chemoresistant disease), primary refractory disease in six patients, and more advanced disease in four patients. Excessive treatment-related toxicity was not noted. There were no cases of interstitial pneumonitis, but three cases of veno-occlusive disease occurred. At 2 years, the estimated overall survival and event-free survival are 50% and 33%. We concluded that BU/CY seems to have sufficient anti- lymphoma activity, is devoid of excessive toxicity and warrants further investigation in this patient population.
Details
- Title: Subtitle
- Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma
- Creators
- M DEMAGALHAES-SILVERMAN - Division of Hematology/Bone Marrow Transplantation, Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, United StatesJ LISTER - Division of Hematology/Bone Marrow Transplantation, Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, United StatesW RYBKA - Division of Hematology/Bone Marrow Transplantation, Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, United StatesJ WILSON - Division of Hematology/Bone Marrow Transplantation, Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, United StatesE BALL - Division of Hematology/Bone Marrow Transplantation, Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
- Resource Type
- Journal article
- Publication Details
- Bone marrow transplantation (Basingstoke), Vol.19(8), pp.777-781
- DOI
- 10.1038/sj.bmt.1700733
- PMID
- 9134168
- NLM abbreviation
- Bone Marrow Transplant
- ISSN
- 0268-3369
- eISSN
- 1476-5365
- Publisher
- Nature Publishing Group
- Language
- English
- Date published
- 1997
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094342302771
Metrics
20 Record Views